TY - JOUR
T1 - Modulators of lysophosphatidic acid signalling
AU - Feng, Li
AU - Mills, Gordon B.
AU - Prestwich, Glenn D.
N1 - Funding Information:
The authors thank the Center for Cell Signaling, (Utah Center of Excellence), Human Frontier Science Program RG0073-2000-B to GD Prestwich, NIH grant HL 070231 to T McIntyre and GD Prestwich and National Institutes of Health Grants CA64602 to GB Mills for financial support of the research in the laboratories. Many of the LPA analogues mentioned herein are commercially available from Avanti Polar Lipids (Alabaster, AL, USA) or from Echelon Biosciences, Inc. (Salt Lake City, UT, USA).
PY - 2003/10
Y1 - 2003/10
N2 - Lysophosphatidic acid (LPA) is a key lipid mediator in the regulation of cell proliferation, cell survival, motility, invasion and wound healing in normal cells, such as fibroblasts and haematopoietic cells. In addition, LPA signalling is implicated in cancer, atherosclerosis, ischaemia perfusion injury and other pathophysiological conditions. LPA, sphingolipids and other lysophospholipids act through several mechanisms: (i) a family of cell-surface seven transmembrane domain G-protein-coupled receptors; (ii) a nuclear hormone-activated transcription factor; (iii) membrane curvature and endocytosis and (iv) other targets yet to be defined. Based on the action of LPA on molecular targets in different human pathologies, both receptor-selective agonists and antagonists are sought as potential clinical agents. In addition, the control of endogenous production and clearance of LPA may provide an important target for treatment of multiple disease states. Thus, modifiers of phospholipase A1 and A2, lysophospholipase D, LPA acyl transferase and lipid phosphate phosphatase activities should be explored as potential therapeutics. This overview summarises the literature and issued patents covering the molecular agents developed to potentially manipulate the specific effects of LPA on cell physiology and clinical outcome.
AB - Lysophosphatidic acid (LPA) is a key lipid mediator in the regulation of cell proliferation, cell survival, motility, invasion and wound healing in normal cells, such as fibroblasts and haematopoietic cells. In addition, LPA signalling is implicated in cancer, atherosclerosis, ischaemia perfusion injury and other pathophysiological conditions. LPA, sphingolipids and other lysophospholipids act through several mechanisms: (i) a family of cell-surface seven transmembrane domain G-protein-coupled receptors; (ii) a nuclear hormone-activated transcription factor; (iii) membrane curvature and endocytosis and (iv) other targets yet to be defined. Based on the action of LPA on molecular targets in different human pathologies, both receptor-selective agonists and antagonists are sought as potential clinical agents. In addition, the control of endogenous production and clearance of LPA may provide an important target for treatment of multiple disease states. Thus, modifiers of phospholipase A1 and A2, lysophospholipase D, LPA acyl transferase and lipid phosphate phosphatase activities should be explored as potential therapeutics. This overview summarises the literature and issued patents covering the molecular agents developed to potentially manipulate the specific effects of LPA on cell physiology and clinical outcome.
KW - Cancer
KW - Cell proliferation
KW - Endothelial differentiation gene (Edg)
KW - Lysophosphatidic acid (LPA)
KW - Lysophospholipid
KW - Peroxisome proliferator-activated receptor-γ (PPAR-γ)
KW - Receptor agonist
KW - Receptor antagonist
UR - http://www.scopus.com/inward/record.url?scp=0242636030&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0242636030&partnerID=8YFLogxK
U2 - 10.1517/13543776.13.10.1619
DO - 10.1517/13543776.13.10.1619
M3 - Review article
AN - SCOPUS:0242636030
SN - 1354-3776
VL - 13
SP - 1619
EP - 1634
JO - Expert Opinion on Therapeutic Patents
JF - Expert Opinion on Therapeutic Patents
IS - 10
ER -